NEWS
AIM Vaccines Submits Two mRNA Blockbuster Single-item Vaccines for Clinical Trials in One Month, Paving the Way for Significant Performance Growth
Shortly after filing for clinical trials of its mRNA RSV (Respiratory Syncytial Virus) vaccine with the U.S. FDA, AIM Vaccines announced on February 11 that its independently developed mRNA shingles vaccine has been submitted to Center for Drug Evaluation (CDE), NMPA for clinical approval. Over the past month, AIM's two major mRNA vaccines have achieved significant milestones.
Looking solely at the advantages of these two blockbuster single-item vaccines, third-party test results from preclinical animal trials showed that AIM's mRNA shingles vaccine demonstrated significantly higher specific T-cell immunity, specific IgG antibody titers, and membrane antigen fluorescence antibody (FAMA) titers than the marketed recombinant subunit control vaccine. Additionally, AIM's mRNA RSV vaccine exhibited significantly higher specific IgG antibody titers, live virus neutralizing antibody potency, and specific T-cell immunity than internationally available mRNA RSV control vaccines.
In terms of the overall advantages of the mRNA platform, AIM Vaccines is at the domestic leading level. As one of the first companies in China to develop mRNA vaccine products, AIM possesses a mature mRNA vaccine R&D system. Its mRNA technology platform has been validated by human clinical trial data from over ten thousand cases of mRNA vaccine products. AIM has now integrated the entire lifecycle of mRNA vaccine R&D and production, enabling rapid industrialization of mRNA vaccine products post-clinical approval and accelerating the commercialization process of vaccine products.
Industry insiders note that AIM's rapid progress in developing mRNA shingles and RSV vaccines highlights the advantages of its mRNA platform and accelerates its global market entry, promising substantial performance growth.
More notably, AIM previously disclosed its use of AI in vaccine antigen structure analysis and mRNA sequence design. Its mRNA platform including but not limited to mRNA vaccines for RSV, shingles, and next-generation rabies vaccines, with R&D directions expanding into non-communicable disease areas such as oncological vaccines.
Looking solely at the advantages of these two blockbuster single-item vaccines, third-party test results from preclinical animal trials showed that AIM's mRNA shingles vaccine demonstrated significantly higher specific T-cell immunity, specific IgG antibody titers, and membrane antigen fluorescence antibody (FAMA) titers than the marketed recombinant subunit control vaccine. Additionally, AIM's mRNA RSV vaccine exhibited significantly higher specific IgG antibody titers, live virus neutralizing antibody potency, and specific T-cell immunity than internationally available mRNA RSV control vaccines.
In terms of the overall advantages of the mRNA platform, AIM Vaccines is at the domestic leading level. As one of the first companies in China to develop mRNA vaccine products, AIM possesses a mature mRNA vaccine R&D system. Its mRNA technology platform has been validated by human clinical trial data from over ten thousand cases of mRNA vaccine products. AIM has now integrated the entire lifecycle of mRNA vaccine R&D and production, enabling rapid industrialization of mRNA vaccine products post-clinical approval and accelerating the commercialization process of vaccine products.
Industry insiders note that AIM's rapid progress in developing mRNA shingles and RSV vaccines highlights the advantages of its mRNA platform and accelerates its global market entry, promising substantial performance growth.
More notably, AIM previously disclosed its use of AI in vaccine antigen structure analysis and mRNA sequence design. Its mRNA platform including but not limited to mRNA vaccines for RSV, shingles, and next-generation rabies vaccines, with R&D directions expanding into non-communicable disease areas such as oncological vaccines.
